The History of Rosuvastatin
Rosuvastatin arrived late to the statin story, yet within a few years it became one of the most prescribed medicines in the world. Its history combines Japanese chemistry, a major pharmaceutical partnership, a public safety controversy and one of the most debated trials in cardiology. Our editorial team traces how it all unfolded.
Before rosuvastatin: how statins began
The statin era began in Japan. In the early 1970s the biochemist Akira Endo, working at Sankyo, screened thousands of fungal extracts looking for substances that block HMG-CoA reductase, the enzyme that controls a key step in cholesterol synthesis. In 1976 he described compactin (mevastatin), isolated from a Penicillium mould.
Compactin itself never reached the market, but it proved the concept. Merck developed lovastatin, which in 1987 became the first statin approved by the US Food and Drug Administration. Simvastatin and pravastatin soon followed, and later atorvastatin, which was fully synthetic and more potent.
The decisive turning point came in 1994 with the Scandinavian Simvastatin Survival Study (4S). It showed that lowering LDL cholesterol in people with coronary heart disease reduced deaths overall, not merely heart attacks. From that moment statins moved from a niche lipid treatment to a pillar of cardiovascular prevention.
By the late 1990s, therefore, the question was no longer whether statins worked, but whether a more powerful molecule could bring more patients to their cholesterol targets with a single tablet.
Discovery at Shionogi and the AstraZeneca deal
Rosuvastatin was synthesised by chemists at Shionogi, an Osaka-based pharmaceutical company, in the 1990s. Their work, published by Watanabe and colleagues in 1997, described a series of pyrimidine-based compounds designed to inhibit HMG-CoA reductase strongly while staying largely out of the cytochrome P450 system that metabolises many other drugs.
In 1998 Shionogi licensed the compound to AstraZeneca, which led the global clinical programme. The molecule was given the development code ZD4522 and later the brand name Crestor.
Several properties made it stand out from earlier statins:
- it is relatively hydrophilic, so it is taken up mainly by liver cells rather than spreading into many tissues;
- it is only minimally metabolised by CYP3A4, reducing some drug-interaction risks seen with simvastatin and atorvastatin;
- it has a long half-life, of the order of 19 hours, allowing once-daily dosing at any time of day;
- milligram for milligram it lowers LDL cholesterol more than older statins.
Pharmacokinetic studies also revealed that people of East and South Asian ancestry tend to have higher blood levels at the same dose. This finding later shaped labelling, with lower starting doses recommended for these groups.
Launch and the early safety debate
The first approval came in the Netherlands in late 2002, followed by the FDA in August 2003 and then other European countries, including the UK, through mutual recognition. Approved tablet strengths were 5, 10, 20 and 40 mg; an 80 mg dose had been tested during development but was not taken forward.
The decision on 80 mg reflected safety signals. At the highest exposures, investigators saw more cases of muscle damage, including rare rhabdomyolysis, and transient protein in the urine. These findings, together with post-marketing reports, prompted a consumer group in the United States to petition for withdrawal in 2004.
Regulators did not withdraw the drug, but they strengthened warnings, emphasised starting at lower doses and highlighted risk factors such as kidney impairment, hypothyroidism, interacting medicines and Asian ancestry. In the UK, the 40 mg strength was restricted to specialist supervision in higher-risk groups.
Imaging trials during this period added a different strand to the story. ASTEROID, published in 2006, used intravascular ultrasound and reported regression of coronary plaque volume with high-intensity rosuvastatin. Such findings fuelled interest in how far LDL lowering could reverse established disease.
JUPITER, HOPE-3 and a new kind of prevention
The trial that defined rosuvastatin was JUPITER, published in the New England Journal of Medicine in 2008. It enrolled nearly 18,000 people without known cardiovascular disease, with LDL cholesterol that was not raised but with elevated high-sensitivity C-reactive protein, a marker of inflammation.
The trial was stopped early after a median follow-up of under two years because rosuvastatin 20 mg daily markedly reduced the combined rate of heart attack, stroke and related events compared with placebo. It strengthened the idea that people at moderate risk, not only those with high cholesterol, can benefit from statins.
JUPITER was also criticised: early stopping can exaggerate benefit, absolute risk reductions were modest, and a small increase in physician-reported diabetes was noted. These debates helped shift attention towards absolute risk and shared decision-making.
In 2016 the HOPE-3 trial, which included participants from many countries, confirmed that rosuvastatin 10 mg reduced cardiovascular events in people at intermediate risk without cardiovascular disease, giving the primary prevention case a broader evidence base.
Rosuvastatin in UK practice today
In the UK, NICE guidance on lipid modification has long favoured atorvastatin as the default high-intensity statin, largely on cost grounds when atorvastatin became generic first. Rosuvastatin is used as an alternative, for example when atorvastatin is not tolerated or when greater LDL reduction is needed.
Once patent protection ended, generic rosuvastatin became widely available on the NHS at low cost, which has increased its use in both primary care and lipid clinics.
| Statin | Relative LDL-lowering intensity | Main metabolic route |
|---|---|---|
| Simvastatin | Low to moderate | CYP3A4 |
| Pravastatin | Low | Limited CYP involvement |
| Atorvastatin | Moderate to high | CYP3A4 |
| Rosuvastatin | Moderate to high | Mostly excreted unchanged; minor CYP2C9 |
Monitoring follows the same pattern as for other statins: a baseline lipid profile, liver enzymes and kidney function, followed by a repeat lipid check after about three months to judge the response.
For physically active readers, it is worth knowing that muscle aches are a commonly reported reason for stopping statins, although randomised blinded studies suggest that most such symptoms are not caused by the drug itself. Persistent muscle pain or dark urine should always be reported promptly.
Editorial conclusions
Rosuvastatin grew out of three decades of statin research that began with Akira Endo’s fungal screening and was transformed by the 4S trial.
Its chemistry offered potent LDL lowering with fewer CYP3A4 interactions, while early safety debates led to more cautious dosing, particularly for higher-risk groups.
JUPITER and HOPE-3 broadened the evidence for statins in primary prevention, though the size of the benefit depends on an individual’s absolute risk.
Readers may also find useful our articles on blood tests during metformin therapy, on the side effects of semaglutide and on blood tests during N-acetylcysteine use.
References
- Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(5):484–493.
- Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–1389.
- Watanabe M, Koike H, Ishiba T, et al. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem. 1997;5(2):437–444.
- Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556–1565.
- Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
- Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2021–2031.
- National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238). London: NICE; 2023.
